



# DRUGGING AUTOPHAGY SUMMIT

## Deciphering the Druggability of Autophagy-Driven Diseases

---

November 19-20th 2020 | EDT Timezone

### Networking Available All Day

9:00am - 5:00pm - Day 1, Wednesday, November 19th

9:00am - 12:15pm - Day 2, Thursday, November 20th

As the main agenda progresses throughout the day, you will have the choice of listening in to / participating in the live content or spend more of your time networking with your peers.

Here is how you will be able to achieve this, outside of the networking sessions on the agenda

- **See who's in the room** - you will be able to message all live attendees and connect with those who respond.
- **Schedule 1-2-1 video calls** with your connections at any time that suits you.

- **Open Networking** - think of this as the event lobby where you can replicate those all-important “water-cooler” moments.

You will be able to hop seamlessly between networking and on-going agenda sessions at any point.

With networking available all day, this will provide you with even more opportunities to meet your potential future partners and collaborators.

**Conference Day 1: Thursday, November 19<sup>th</sup>.**

Location: **Stage**

**Deciphering the Fundamental Biology of Autophagy**

9:00am **Chair’s Opening Remarks & Setting the Scene**

- How has the industry progressed over the last 12 months?
- What should we expect to have learned by the end of Drugging Autophagy 2020?

**Alec Kimmelman**, Professor and Chair of the Department of Radiation Oncology/Founder and Scientific Consultant, [NYU Langone Medical Center/Vescor Therapeutics](#)

9:05am Keynote Presentation - **Drugging Autophagy: How Far Have We Come and How Far Do We Have to Go?**

- A comprehensive review of the autophagy pathway and the common challenges of drugging autophagy
- What are the pros and cons of modulating both general and specific autophagy?
- Hear about the growing number of cancer clinical trials involving hydroxychloroquine
- A look towards dimeric chloroquines that target PPT1, currently in preclinical development at Pinpoint Therapeutics

**Ravi Amarvadi**, Associate Professor of Medicine/Co-Leader, [University of Pennsylvania/Cancer Therapeutics Program Abramson Cancer Center](#)

9:25am Wellness Break

Get-up and have a stretch before the next session begins.

9:30am Panel Discussion - **How Much is Our Understanding of the Fundamental Biology Impacting the Druggability of Autophagy?**

- In which clinical contexts should autophagy be inhibited or enhanced?
- How are we being limited by our incomplete understanding of autophagy pathways?
- Which nodes of the autophagy pathway need better characterization to improve pathway druggability?
- Are our current model systems limiting our progression? How can these models be improved?
- What do we hope to achieve by the end of the summit?

**Jorge Moscat**, Vice Chair for Experimental Pathology, [Weill Cornell Medicine](#)

**Magdalene Moran**, President & CSO, [Caraway Therapeutics](#)

**Vojo Deretic**, Director, [Autophagy, Inflammation and Metabolism Center of Biomedical Research Excellence \(AIM Center\)](#)

10:00am **Life Admin Break**

Location: **Sessions**

Catch-up on emails, let the dog out, brew some more coffee... use this time to take care of regular day-to-day life.

10:00am **Open Q&A with Speakers**

This is your chance to pose your burning questions to the expert speakers from the previous panel.

**Jorge Moscat**, Vice Chair for Experimental Pathology, [Weill Cornell Medicine](#)

**Magdalene Moran**, President & CSO, [Caraway Therapeutics](#)

**Vojo Deretic**, Director, [Autophagy, Inflammation and Metabolism Center of Biomedical Research Excellence \(AIM Center\)](#)

**Actively or passively take part in this session.**

Location: **Networking**

10:20am **Speed Networking**

In the purpose-built Networking area, get ready to expand your network through randomly assigned 1 on 1 quick-fire video meetings. You can choose who you want to “connect” with and then set-up 1-2-1 in-depth catch-up’s throughout the rest of the event.

This function also ensures that you don’t meet the same person more than once, allowing you to meet as many fellow attendees as you desire.

Your future collaborators or partners could be just one click away!

Location: **Stage**

**Autophagy Showcase: Crucial Case Studies**

10:50am Presentation - **Targeting TRPML1 for Neurodegenerative Disease**

- An overview of the role of TRPML1 in cellular clearance
- Why increasing autophagy is an exciting therapeutic strategy for neurodegenerative diseases
- A look at Caraway's TRPML1 program and the cellular effects of enhancing channel function

**Magdalene Moran**, President & CSO, [Caraway Therapeutics](#)

11:10am Presentation - **Non-ATG Factors that Control Autophagy in Disease**

- Hear about IRGM and its role in immunity, Crohn's Disease, tuberculosis and autophagy
- Discussion will include galectins and the control of the upstream regulators of autophagy mTOR and AMPK
- A look at membrane damage and the coordinated role of autophagy and ESCRTs

**Vojo Deretic**, Director, [Autophagy, Inflammation and Metabolism Center of Biomedical Research Excellence \(AIM Center\)](#)

11:30am Wellness Break

Get-up and have a stretch before the next session begins.

11:40am Presentation - **Enhancing Autophagy for the Treatment of Cystic Fibrosis**

- Hear about Catabasis' autophagy preclinical candidate, CAT-5571, for cystic fibrosis and other pulmonary diseases
- Discussion will focus on CAT-5571's journey from discovery to preclinical development
- Learn how the oral small molecule has been shown to restore autophagy, re-establish host defense and increase pathogen clearance in preclinical model systems

**Andrew Nichols, CSO, [Catabasis Pharmaceuticals](#)**

12:00pm Presentation - **Blocking Autophagy in RAS-Driven Cancers**

- Hear how the discovery that solid tumors use autophagy as a survival mechanism has made huge waves in oncology
- Discussion will focus on how autophagy inhibition enhances responsiveness to MAPK-pathway targeted therapies
- A look at current clinical trials in pancreatic cancer, lung cancer and melanoma

**Martin McMahon, Cumming-Presidential Chair of Cancer Biology/Senior Director for Preclinical Translation, [University of Utah](#)**

12:20pm **Lunch**

Finally, a lunch at a conference that is completely your choice!

Use this extended break to have your regular lunch, spend time with your family and give your brain a break. Recharge for the afternoon session.

Location: **Sessions**

12:20pm-12:40pm **Open Q&A with Speakers**

This is your chance to pose your burning questions to the expert presenters from the previous session.

**Magdalene Moran**, President & CSO, [Caraway Therapeutics](#)

**Vojo Deretic**, Director, [Autophagy, Inflammation and Metabolism Center of Biomedical Research Excellence \(AIM Center\)](#)

**Andrew Nichols**, CSO, [Catabasis Pharmaceuticals](#)

**Martin McMahon**, Cumming-Presidential Chair of Cancer Biology/Senior Director for Preclinical Translation, [University of Utah](#)

**Actively or passively take part in this session.**

---

The Drugging Autophagy Summit includes an extended break in the middle to give you ample time for lunch and another chance to catch-up on the day job. Or if you have time, you can use this break for 1-2-1 meetings or open networking.

---

Location: **Stage**

**Drug Discovery and Screening**

2:00pm Presentation – **Discovery of ULK1/2 Inhibitor DCC-3116 for Treatment of RAS-Driven Cancers**

- An overview of Deciphera’s Switch Control Inhibitor drug discovery platform
- An inside look at the discovery of the ULK 1/2 inhibitor DCC-3116
- Discussion will include preclinical data supporting potential clinical utility in treatment of RAS-driven cancers

**Daniel L. Flynn**, Founder and CSO, [Deciphera Pharmaceuticals, LLC](#)

2:20pm Presentation - **Targeting the Hallmarks of Aging**

- A look at how Samsara is working to extend healthy lifespan through Caloric Restriction Mimetic small molecules in the labs of Guido Kroemer and Frank Madeo
- Hear about the largest ever phenotypic screen for autophagy enhancers and meditations on target ID
- Discussion will cover developing drugs for multiple age-related diseases - “pipeline-in-a-pill”

**Jens Eckstein**, Interim CEO, President & Director, [Samsara Therapeutics](#)

2:40pm Wellness Break

Get-up and have a stretch before the next session begins.

2:45pm Presentation - **Autophagy Drug Discovery for Dementia**

- Hear about the research over at the ALBORADA Drug Discovery Institute into disease modifying therapies for the diseases that cause dementia
- A look at the Institute’s focus on understanding and manipulating proteostasis
- Discussion will cover their capabilities in plate-based screening, cell-based assays and phenotypic screens

**James Duce**, Head of Biology, [ALBORADA Drug Discovery Institute](#)

3:05pm **Life Admin Break**

Location: **Sessions**

Catch-up on emails, let the dog out, brew some more coffee... use this time to take care of regular day-to-day life.

3:05pm **Open Q&A with Speakers**

This is your chance to pose your burning questions to the expert speakers from the previous panel.

**Actively or passively take part in this session.**

**Daniel L. Flynn**, Founder and CSO, [Deciphera Pharmaceuticals, LLC](#)

**Jens Eckstein**, Interim CEO, President & Director, [Samsara Therapeutics](#)

**James Duce**, Head of Biology, [ALBORADA Drug Discovery Institute](#)

Location: **Stage**

3:20pm Presentation - **Chemical Modulation of Chaperone-Mediated Autophagy**

- An overview of the chaperone-mediated autophagy pathway (CMA) and its regulation
- Discussion will focus on a chemical biology strategy to modulate CMA
- Hear about ongoing efforts to enhance CMA in neurodegenerative diseases and inhibit CMA in cancer

**Evrpidis Gavathiotis**, Professor of Biochemistry and Medicine/Co-founder, [Albert Einstein College of Medicine/Selphagy Therapeutics](#)

3:40pm Panel Discussion - **How Should We Drug Autophagy?**

- To inhibit or enhance autophagy?

- What do we need to consider when using non-specific non-potent inhibitors like chloroquine?
- Should we be focusing on the most autophagy-dependent disease states?
- Is general autophagy's accessibility worth the trade-off with off-target effects?
- How should academics, biotech, and pharma be working together to advance the industry?

**Andrew Nichols**, CSO, [Catabasis Pharmaceuticals](#)

**Daniel L. Flynn**, Founder & CSO, [Deciphera Pharmaceuticals, LLC](#)

**Fiona Menzies**, Research Advisor & Head of Proteostasis, [Eli Lilly](#)

**Ravi Amarvadi**, Associate Professor of Medicine/Co-Leader, [University of Pennsylvania/Cancer Therapeutics Program Abramson Cancer Center](#)

### Location: **Networking & Sessions**

4:10:pm - 5:00pm **Virtual Drinks**

Share a virtual drink with old friends or new connections. At small virtual tables, this is your chance to casually interact with the rest of the Drugging Autophagy industry.

### Location: **Sessions**

4:10pm - 4:30pm **Open Q&A with Speakers**

This is your chance to pose your burning questions to the expert speakers from the previous panel.

**Actively or passively take part in this session.**

**Andrew Nichols**, CSO, [Catabasis Pharmaceuticals](#)

**Daniel L. Flynn**, Founder & CSO, [Deciphera Pharmaceuticals, LLC](#)

**Fiona Menzies**, Research Advisor & Head of Proteostasis, [Eli Lilly](#)

**Ravi Amarvadi**, Associate Professor of Medicine/Co-Leader, [University of Pennsylvania/Cancer Therapeutics Program Abramson Cancer Center](#)

---

**Conference Day 2: Friday, November 20<sup>th</sup>.**

Location: **Stage**

**Modeling Autophagy**

9:00am **Chair's Opening Remarks**

- Recap of Day 1 – what lessons have been learnt already and what discussions stood out?
- A look ahead at Day 2 – what can we expect to learn today?

**Andrew Thorburn**, Professor & Chair, Department of Pharmacology, [University of Colorado](#)

9:05am Presentation - **Understanding the Molecular Mechanisms of Immunosuppression by Autophagy**

- Learn how autophagy in the innate immune system suppresses major inflammatory signaling pathways
- A look at the autophagy gene ATG16L1 and its impact on sterile inflammation, anti-microbial and anti-tumor immunity
- Discussion will focus on novel genomics and proteomics methods used by the Murthy lab to reveal targets of autophagy during the innate immune response

**Aditya Murthy**, Senior Scientist, Department of Cancer Immunology, [Genentech, Inc.](#)

9:25am Presentation - **Targeting Autophagy to Lower Blood Glucose in a Model of Diabetes**

- A look at the interplay between autophagy and time in the control of blood glucose
- Are we able to take advantage of this interplay in lowering blood glucose levels?
- Discussion will include the potential and druggability of this target in humans

**Rajat Singh**, Associate Professor of Medicine and Molecular Pharmacology, [Albert Einstein College of Medicine](#)

9:45am **Life Admin Break**

Catch-up on emails, let the dog out, brew some more coffee... use this time to take care of regular day-to-day life.

Location: **Sessions**

9:45am **Open Q&A with Speakers**

This is your chance to pose your burning questions to the expert presenters from the previous session.

**Aditya Murthy**, Senior Scientist, Department of Cancer Immunology, [Genentech, Inc.](#)

**Rajat Singh**, Associate Professor of Medicine and Molecular Pharmacology, [Albert Einstein College of Medicine](#)

**Actively or passively take part in this session.**

Location: **Stage**

**Autophagy in the Clinic**

10:05am Presentation - **Yin and Yang: Autophagy and the Secretory Pathways as a Biomarker**

- A look at the crosstalk between the autophagy and secretory pathways
- How can we use this relationship to develop a non-invasive surrogate biomarker for autophagy?
- What would this mean for clinical trials in autophagy?

**Jayanta (Jay) Debnath**, Distinguished Professor and Chair of Pathology, [University of California, San Francisco](#)

10:25am Presentation - **ABTL0812: A Novel Pro-Autophagic Drug in Phase 2 Clinical Trials**

- Hear about Ability Pharmaceutical's discovery of ABTL0812
- Discussion will focus on biomarkers in both a preclinical and clinical setting
- A look at the potentiation of chemotherapy, a key point in current therapeutic strategy

**Carles Domènech**, Executive Chairman, CSO & Co-Founder, [Ability Pharmaceuticals](#)

Location: **Sessions**

10:45am **Open Q&A with Speakers**

This is your chance to pose your burning questions to the expert presenters from the previous session.

**Jayanta (Jay) Debnath**, Distinguished Professor and Chair of Pathology, [University of California, San Francisco](#)

**Carles Domènech**, Executive Chairman, CSO & Co-Founder, [Ability Pharmaceuticals](#)

**Actively or passively take part in this session.**

11:05am **Life Admin Break**

Catch-up on emails, let the dog out, brew some more coffee... use this time to take care of regular day-to-day life.

Location: **Stage**

**Industry Leaders Discussion**

11:25am Panel and Open Q&A - **What Do We Need to Achieve Next?**

- What gaps do we need to fill in fundamental biology?
- To enhance or inhibit autophagy: how to delineate between enhancing and inhibiting, and what research needs to be done?
- Which disease states should we focus on, and should we be targeting the most susceptible indications within these disease states?
- How would discovering an 'autophagy signature' impact on moving drugs through the clinic?
- Where should we focus our efforts with regard to model systems and the 'autophagy signature'?
- How can biotechs, academics and pharma work together to advance the industry?

**Moderator: John Skidmore**, CSO, [Alzheimer's Research UK Cambridge Drug Discovery Institute](#)

**Christian Peters**, CEO, [Pinpoint Therapeutics](#)

**Sean Smith**, Executive Director of Neuroscience, [Merck](#)

**Martin McMahon**, Cumming-Presidential Chair of Cancer Biology/Senior Director for Preclinical Translation, [University of Utah](#)

**Jayanta (Jay) Debnath**, Distinguished Professor and Chair of Pathology, [University of California, San Francisco](#)

Location: **Sessions**

11:55am **Open Q&A with Speakers**

This is your chance to pose your burning questions to the expert presenters from the previous session.

**John Skidmore**, CSO, [Alzheimer's Research UK Cambridge Drug Discovery Institute](#)

**Christian Peters**, CEO, [Pinpoint Therapeutics](#)

**Sean Smith**, Executive Director of Neuroscience, [Merck](#)

**Martin McMahon**, Cumming-Presidential Chair of Cancer Biology/Senior Director for Preclinical Translation, [University of Utah](#)

**Jayanta (Jay) Debnath**, Distinguished Professor and Chair of Pathology, [University of California, San Francisco](#)

**Actively or passively take part in this session.**

12:15pm Close of Drugging Autophagy 2020

Roll straight into your weekend with no fight to catch!